Ionis has gained US Food and Drug Administration approval for Tryngolza, making it the first treatment in the US for the rare metabolic disease familial chylomicronemia syndrome (FCS), and giving it a head start over rival Arrowhead.
Ionis To Get Head Start On Arrowhead With Tryngolza Launch
The antisense oligonucleotide specialist is ready to launch its rare disease therapy Tryngolza but could face competition from a more potent rival by mid-2025.
More from New Products
More from Scrip
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
Recent moves in the industry include C-suite changes at Cronos and Accuryn Medical, plus Dyne Therapeutics Acquires Chief Financial Officer From Editas Medicine.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.